Allergan switches to all-cash for Kythera buy; Endo sheds 'non-core' portfolio;

@FiercePharma: Lilly faces first trial over claims of Cymbalta withdrawal symptoms. Report | Follow @FiercePharma

@EricPFierce: FDA may add Baxter saline Mexico plant to U.S. supply. Now if Baxter can just quit having to recall saline. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: DME data helps Eylea soar in Q2--and poach market share from its Roche rivals. Article | Follow @CarlyHFierce

> Allergan ($AGN) said its pending buyout of Kythera Biopharmaceuticals ($KYTH) will now be an all-cash deal rather than an 80/20 cash and stock transaction. Release

> Endo ($ENDP) hived off a portfolio of device, vaccine and other "non-core" products from its South Africa-based subsidiary to an investment consortium, aiming to zero in further on specialty meds. Release

> Mallinckrodt ($MNK) saw its second-quarter profits soar as its specialty drug sales racked up gains from recent dealmaking, but overall sales fell short of analyst expectations on slowing Acthar growth. Report

> AMAG Pharmaceuticals ($AMAG) said it would sell $450 million in notes due 2023 to help finance its buyout of Cord Blood Registry. Release

> Orexo said its opioid addiction drug Zubsolv lost its spot on CVS Health's ($CVS) 2016 standard formulary. Release

Medical Device News

@FierceMedDev: Mevion moves on from IPO to up to $200M JV backed by China, U.S. investors. Article | Follow @FierceMedDev

@StacyALawrence: Boston Sci ups cardiac monitoring, partners with wearable patch startup Preventice. Story | Follow @StacyALawrence

@VarunSaxena2: IYCMI: Citing cybersecurity concerns, FDA says not to use Hospira infusion pump. Article | Follow @VarunSaxena2

@EmilyWFierce: FDA doubles down on duodenoscope safety with list of cleaning recs. Report | Follow @EmilyWFierce

> Israeli biotech gets $27M to back pivotal trial of gelatin-based GI surgical sealant. News

> Med tech megamergers haven't translated to massive layoffs--at least not yet. Editor's corner

Biotech News

@FierceBiotech: Baxalta to Shire: The answer is still 'no.' Article | Follow @FierceBiotech

@JohnCFierce: Mystery solved: Star biotech team rallies behind a $36M diabetes spinout from Salk. Article | Follow @JohnCFierce

@DamianFierce: "IPO (n.): An acronym for 'initial public offering' that neglects to mention the taking." More | Follow @DamianFierce

> Cannabis patch startup plots a $42M IPO to fund drugs for epilepsy, pain. Story

> Judge orders a halt to Alzheimer's spat as Eli Lilly chooses sides in dispute. Article

> Intec Pharma stumbles to $30M IPO as Parkinson's program fails to excite investors. More

Biotech Research News

> Study IDs a new pathway for drug research into calorie-burning brown fat. Report

> Scripps team finds a drug that fights addiction by eliminating memories. More

> BU researchers identify a new, more precise target for breast cancer. Story

> Virus-like nanoparticle vaccine used to guard against RSV. Item

> Uppsala University points to anti-inflammatory IL-35 as beneficial in pre-clinical Type 1 diabetes. Article

Diagnostics News

> UC Berkeley researchers create faster form of DNA amplification using LED lighting. Article

> NIH study finds blood biomarker for traumatic brain injury using sensitive analyzer. Story

> Foundation Medicine trips in Q2 with sluggish test reimbursement. More

> OraSure gets FDA nod for emergency use of rapid Ebola test. Report

> Illumina sends off first three companies from genomics startup incubator. Article

Pharma Marketing News

> Allergan taps purple-haired millennial mascot for hashtag-heavy women's health push. Story

> CVS creates one-on-one diabetes rivalries with new formulary exclusions. Report

> Pharma leaves ad agencies behind for in-house digital marketing teams. More

> Pfizer nabs rights to Copaxone copycats, setting up head-to-head generics fight with Novartis. Story

> Slam dunk: Novo Nordisk re-signs NBA Hall of Famer for Victoza marketing. Article

And Finally ... Drugmakers may need to redefine their notions about market access to maximize growth in emerging markets. Report